Posted On: 2/17/2009
KANSAS CITY, Mo. – Mounting cost pressures, a vast pool of talented scientists in other nations around the world and increasingly abundant opportunities for collaboration with other companies in emerging markets have spurred Western pharmaceutical companies to shift much of the manufacturing operations and clinical-trial work to India and China.
Yet, according to a report issued recently by the Kansas City-based Ewing Marion Kauffman Foundation on the globalization of the pharmaceutical industry, many of the largest, U.S.-based drug and consumer-products companies, including Merck & Co. Inc., Eli Lilly & Co. and Johnson & Johnson Inc., are now counting on the two Asian countries for advanced research and development, as well.
The study, titled “The Globalization of Innovation: Pharmaceuticals – Can India and China Cure the Global Pharmaceutical Market?” reports that Indian and Chinese scientists are rapidly developing the ability to innovate and create their own intellectual property as a result of Western companies shifting their research and development operations to the two countries. In fact, several non-Indian firms with business units in India and China are performing advanced discovery and have begun to move into the “highest-value segments of the pharmaceutical global value chain,” according to the study.
More:
http://www.indusbusinessjournal.com/ME2/dirmod.asp?sid=&nm=&type=Publishing&mod=Publications%3A%3AArticle&mid=8F3A7027421841978F18BE895F87F791&tier=4&id=228976C360764EC98E84D6EA245C130C